Undervalued Biotechnology Stocks on TSX January 2025

January 12, 2025

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

TSX Venture Exchange

The TSX Venture Exchange is a stock exchange headquartered in Calgary, Alberta, Canada. It is an exchange for the securities of early-stage businesses.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
RP RepliCel Life Sciences 0.01 0.06 277.00 30455 1 0.00 0.0
MRVL Marvel Biosciences 0.15 0.27 72.63 31649 7 0.00 0.0
GSD Devonian Health Gr 0.17 0.27 61.93 8261 24 0.00 0.0
XRTX XORTX Therapeutics 1.85 2.80 51.57 2007 5 0.00 10.7
COV Covalon Technologies 3.20 3.52 10.15 36964 80 0.00 29.1
ARCH Arch Biopartners 1.95 2.06 5.64 14315 122 0.00 0.0
SBM Sirona Biochem 0.06 0.06 5.50 32380 16 0.00 0.0
CYTO Cytophage Technologies 0.27 0.28 5.18 40229 15 0.00 0.0
WAVE Waverley Pharma 0.01 0.02 3.41 19621 1 0.00 0.0
TTI Thiogenesis Therapeutics 0.57 0.58 1.22 9597 26 0.00 0.0
All data provided as at market close January 09, 2025.

Company Details

RepliCel Life Sciences

RP:TSX-V

Close Price

0.01

Our Valuation

0.06

% Difference

277.00

Market Cap ($M)

1

P/E Ratio

0.0

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles.

Access the stockcalc valuation


Marvel Biosciences

MRVL:TSX-V

Close Price

0.15

Our Valuation

0.27

% Difference

72.63

Market Cap ($M)

7

P/E Ratio

0.0

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis.

Access the stockcalc valuation


Devonian Health Gr

GSD:TSX-V

Close Price

0.17

Our Valuation

0.27

% Difference

61.93

Market Cap ($M)

24

P/E Ratio

0.0

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector.

Access the stockcalc valuation


XORTX Therapeutics

XRTX:TSX-V

Close Price

1.85

Our Valuation

2.80

% Difference

51.57

Market Cap ($M)

5

P/E Ratio

10.7

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Covalon Technologies

COV:TSX-V

Close Price

3.20

Our Valuation

3.52

% Difference

10.15

Market Cap ($M)

80

P/E Ratio

29.1

Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes and save lives in the areas of infection management, wound care, and surgical procedures. The company generates its revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products are CovaClear, IV IV Clear, SurgiClear, and VALGuard.

Access the stockcalc valuation


Arch Biopartners

ARCH:TSX-V

Close Price

1.95

Our Valuation

2.06

% Difference

5.64

Market Cap ($M)

122

P/E Ratio

0.0

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway.

Access the stockcalc valuation


Sirona Biochem

SBM:TSX-V

Close Price

0.06

Our Valuation

0.06

% Difference

5.50

Market Cap ($M)

16

P/E Ratio

0.0

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.

Access the stockcalc valuation


Cytophage Technologies

CYTO:TSX-V

Close Price

0.27

Our Valuation

0.28

% Difference

5.18

Market Cap ($M)

15

P/E Ratio

0.0

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants.

Access the stockcalc valuation


Waverley Pharma

WAVE:TSX-V

Close Price

0.01

Our Valuation

0.02

% Difference

3.41

Market Cap ($M)

1

P/E Ratio

0.0

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.

Access the stockcalc valuation


Thiogenesis Therapeutics

TTI:TSX-V

Close Price

0.57

Our Valuation

0.58

% Difference

1.22

Market Cap ($M)

26

P/E Ratio

0.0

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
RepliCel Life Sciences and Marvel Biosciences are the most undervalued Biotechnology stocks on the TSX. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-january-2025
RepliCel Life Sciences $RP and Marvel Biosciences $MRVL are the most undervalued Biotechnology stocks on the #TSX. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-january-2025
RepliCel Life Sciences and Marvel Biosciences are the most undervalued Biotechnology stocks on the TSX. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-january-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.